Haque M, Yoshida EM

Idioma: Español
Referencias bibliográficas: 7
Paginas: 78-79
Archivo PDF: 97.17 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Di Bisceglie AM, Shiffman ML, Everson GT, et al. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med 2008; 359(23): 2429-41.

2. Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med 1998; 129: 94-99.

3. Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-81.

4. Yoshida EM, Sherman M, Bain V, et al. Retreatment with pegylated interferon alpha-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroetrol 2009; 23 (in press).

5. Poynard T, Schiff E, Terg R, et al. Sustained viral response (SVR) is dependent on baseline characteristics in the retreatment of previously alfa interferon/ribavirin (I/R) nonrsponders (NR): final results from the EPIC 3 program. J Hepatol 2008; 48(Suppl 2): S369.

6. Lawitz E, Rodriguez-Torres M, Muir AJ, et al. Antiviral effects and safety of telaprevir, peginterferon alfa-2a, and ribavirin for 28 days in hepatitis C patients. J Hepatol 2008; 49(2): 163-9.

7. Kwo P. Interim results from hcv sprint-1: rvr/evr from phase 2 study of boceprevir plus pegintron(tm) (peginterferon alfa-2b)/ribavirin in treatment naive subjects with genotype-1 chc. J Hepatol 2008; 48(Suppl 2): S372.